Patents by Inventor Thomas Shih

Thomas Shih has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • C1 to C4 side chain modified nodulisporic acid analogs
    Patent number: 6586452
    Abstract: The present invention relates to novel nodulosporic acid derivatives, which are acaricidal, antiparasitic, insecticidal and anthelmintic agents.
    Type: Grant
    Filed: July 9, 2001
    Date of Patent: July 1, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Thomas Shih, Steven L. Colletti, Michael H. Fisher, Peter T. Meinke, Howard C. H. Kuo, Prasun K. Chakravarty, Matthew J. Wyvratt, Sriram Tyagarajan, Richard Berger
  • C4 side-chain modified nodulisporic acid analogs
    Publication number: 20020045653
    Abstract: The present invention relates to novel nodulosporic acid derivatives, which are acaricidal, antiparasitic, insecticidal and anthelmintic agents.
    Type: Application
    Filed: July 9, 2001
    Publication date: April 18, 2002
    Inventors: Thomas Shih, Steven L. Colletti, Michael H. Fisher, Peter T. Meinke, Dong Ok, Prasun K. Chakravarty, Matthew J. Wyvratt
  • Nodulisporic acid derivatives
    Patent number: 5962499
    Abstract: The present invention relates to novel nodulosporic acid derivatives, which are acaricidal, antiparasitic, insecticidal and anthelmintic agents.
    Type: Grant
    Filed: March 23, 1998
    Date of Patent: October 5, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Peter T. Meinke, Thomas Shih, Michael H. Fisher
  • Substituted sulfonamides as selective .beta.-3 agonists for the treatment of diabetes and obesity
    Patent number: 5705515
    Abstract: Substituted sulfonamides are selective .beta..sub.3 adrenergic receptor agonists with very little .beta..sub.1 and .beta..sub.2 adrenergic receptor activity and as such the compounds are capable of increasing lipolysis and energy expenditure in cells. The compounds thus have potent activity in the treatment of Type II diabetes and obesity. The compounds can also be used to lower triglyceride levels and cholesterol levels or raise high density lipoprotein levels or to decrease gut motility. In addition, the compounds can be used to reduced neurogenic inflammation or as antidepressant agents. The compounds are prepared by coupling an aminoalkylphenyl-sulfonamide with an appropriately substituted epoxide. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for increasing gut motility are also disclosed.
    Type: Grant
    Filed: July 25, 1996
    Date of Patent: January 6, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Michael H. Fisher, Elizabeth M. Naylor, Emma R. Parmee, Thomas Shih, Hyun Ok, Ann E. Weber
  • Substituted sulfonamides as selective .beta..sub.3 agonists for the treatment of diabetes and obesity
    Patent number: 5561142
    Abstract: Substituted sulfonamides are selective .beta..sub.3 adrenergic receptor agonists with very little .beta..sub.1 and .beta..sub.2 adrenergic receptor activity and as such the compounds are capable of increasing lipolysis and energy expenditure in cells. The compounds thus have potent activity in the treatment of Type II diabetes and obesity. The compounds can also be used to lower triglyceride levels and cholesterol levels or raise high density lipoprotein levels or to decrease gut motility. In addition, the compounds can be used to reduced neurogenic inflammation or as antidepressant agents. The compounds are prepared by coupling an aminoalkylphenyl-sulfonamide with an appropriately substituted epoxide. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for increasing gut motility are also disclosed.
    Type: Grant
    Filed: May 22, 1995
    Date of Patent: October 1, 1996
    Assignee: Merck & Co., Inc.
    Inventors: Michael H. Fisher, Elizabeth M. Naylor, Dong Ok, Ann E. Weber, Thomas Shih, Hyun Ok